Literature DB >> 18973914

Evolution of proviral gp120 over the first year of HIV-1 subtype C infection.

Vladimir Novitsky1, Stephen Lagakos, Michaela Herzig, Caitlin Bonney, Lemme Kebaabetswe, Raabya Rossenkhan, David Nkwe, Lauren Margolin, Rosemary Musonda, Sikhulile Moyo, Elias Woldegabriel, Erik van Widenfelt, Joseph Makhema, M Essex.   

Abstract

The evolution of proviral gp120 during the first year after seroconversion in HIV-1 subtype C infection was addressed in a case series of eight subjects. Multiple viral variants were found in two out of eight cases. Slow rate of viral RNA decline and high early viral RNA set point were associated with a higher level of proviral diversity from 0 to 200 days after seroconversion. Proviral divergence from MRCA over the same period also differed between subjects with slow and fast decline of viral RNA, suggesting that evolution of proviral gp120 early in infection may be linked to the level of viral RNA replication. Changes in the length of variable loops were minimal, and length reduction was more common than length increase. Potential N-linked glycosylation sites ranged +/-one site, showing common fluctuations in the V4 and V5 loops. These results highlight the role of proviral gp120 diversity and diversification in the pathogenesis of acute HIV-1 subtype C infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18973914      PMCID: PMC2642736          DOI: 10.1016/j.virol.2008.09.017

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  70 in total

1.  A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood.

Authors:  Stéphane Guindon; Olivier Gascuel
Journal:  Syst Biol       Date:  2003-10       Impact factor: 15.683

2.  Envelope diversity, coreceptor usage and syncytium-inducing phenotype of HIV-1 variants in saliva and blood during primary infection.

Authors:  Stephanie A Freel; Susan A Fiscus; Christopher D Pilcher; Prema Menezes; Julieta Giner; Ericka Patrick; Jeffrey L Lennox; Charles B Hicks; Joseph J Eron; Diane C Shugars
Journal:  AIDS       Date:  2003-09-26       Impact factor: 4.177

3.  Model selection and model averaging in phylogenetics: advantages of akaike information criterion and bayesian approaches over likelihood ratio tests.

Authors:  David Posada; Thomas R Buckley
Journal:  Syst Biol       Date:  2004-10       Impact factor: 15.683

4.  Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B.

Authors:  Simon D W Frost; Yang Liu; Sergei L Kosakovsky Pond; Colombe Chappey; Terri Wrin; Christos J Petropoulos; Susan J Little; Douglas D Richman
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

5.  Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels.

Authors:  Bhavna Chohan; Dorothy Lang; Manish Sagar; Bette Korber; Ludo Lavreys; Barbra Richardson; Julie Overbaugh
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

6.  Heterosexual transmission of multiple highly conserved viral variants in HIV-1 subtype C-infected seronegative women.

Authors:  Cecilia Rademeyer; Joanne H van Harmelen; Gita Ramjee; Salim Sabdool Karim; Carolyn Williamson
Journal:  AIDS       Date:  2004-10-21       Impact factor: 4.177

7.  Adaptation in the env gene of HIV-1 and evolutionary theories of disease progression.

Authors:  Scott Williamson
Journal:  Mol Biol Evol       Date:  2003-05-30       Impact factor: 16.240

8.  Comparative study of adaptive molecular evolution in different human immunodeficiency virus groups and subtypes.

Authors:  Marc Choisy; Christopher H Woelk; Jean-François Guégan; David L Robertson
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

9.  Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression.

Authors:  Manish Sagar; Ludo Lavreys; Jared M Baeten; Barbra A Richardson; Kishorchandra Mandaliya; Bhavna H Chohan; Joan K Kreiss; Julie Overbaugh
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

10.  Dual HIV-1 infection associated with rapid disease progression.

Authors:  Geoffrey S Gottlieb; David C Nickle; Mark A Jensen; Kim G Wong; Jandre Grobler; Fusheng Li; Shan-Lu Liu; Cecilia Rademeyer; Gerald H Learn; Salim S Abdool Karim; Carolyn Williamson; Lawrence Corey; Joseph B Margolick; James I Mullins
Journal:  Lancet       Date:  2004-02-21       Impact factor: 79.321

View more
  28 in total

1.  Evolutionary gamut of in vivo Gag substitutions during early HIV-1 subtype C infection.

Authors:  Vladimir Novitsky; Rui Wang; Jeannie Baca; Lauren Margolin; Mary F McLane; Sikhulile Moyo; Erik van Widenfelt; Joseph Makhema; M Essex
Journal:  Virology       Date:  2011-10-19       Impact factor: 3.616

2.  Long-Range HIV Genotyping Using Viral RNA and Proviral DNA for Analysis of HIV Drug Resistance and HIV Clustering.

Authors:  Vlad Novitsky; Melissa Zahralban-Steele; Mary Fran McLane; Sikhulile Moyo; Erik van Widenfelt; Simani Gaseitsiwe; Joseph Makhema; M Essex
Journal:  J Clin Microbiol       Date:  2015-06-03       Impact factor: 5.948

3.  Intercompartmental recombination of HIV-1 contributes to env intrahost diversity and modulates viral tropism and sensitivity to entry inhibitors.

Authors:  Richard J P Brown; Paul J Peters; Catherine Caron; Maria Paz Gonzalez-Perez; Leanne Stones; Chiambah Ankghuambom; Kemebradikumo Pondei; C Patrick McClure; George Alemnji; Stephen Taylor; Paul M Sharp; Paul R Clapham; Jonathan K Ball
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

4.  Importance of Viral Sequence Length and Number of Variable and Informative Sites in Analysis of HIV Clustering.

Authors:  Vlad Novitsky; Sikhulile Moyo; Quanhong Lei; Victor DeGruttola; M Essex
Journal:  AIDS Res Hum Retroviruses       Date:  2015-02-06       Impact factor: 2.205

5.  Dynamics and timing of in vivo mutations at Gag residue 242 during primary HIV-1 subtype C infection.

Authors:  Vladimir Novitsky; Rui Wang; Lauren Margolin; Jeannie Baca; Sikhulile Moyo; Rosemary Musonda; M Essex
Journal:  Virology       Date:  2010-05-04       Impact factor: 3.616

6.  Intra-host evolutionary rates in HIV-1C env and gag during primary infection.

Authors:  Vlad Novitsky; Rui Wang; Raabya Rossenkhan; Sikhulile Moyo; M Essex
Journal:  Infect Genet Evol       Date:  2013-03-20       Impact factor: 3.342

7.  Subtle evolutionary changes in the distribution of N-glycosylation sequons in the HIV-1 envelope glycoprotein 120.

Authors:  R Shyama Prasad Rao; Bernd Wollenweber
Journal:  Int J Biol Sci       Date:  2010-07-21       Impact factor: 6.580

8.  HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the "test-and-treat" approach to reduce HIV transmission.

Authors:  Vladimir Novitsky; Rui Wang; Hermann Bussmann; Shahin Lockman; Marianna Baum; Roger Shapiro; Ibou Thior; Carolyn Wester; C William Wester; Anthony Ogwu; Aida Asmelash; Rosemary Musonda; Adriana Campa; Sikhulile Moyo; Erik van Widenfelt; Madisa Mine; Claire Moffat; Mompati Mmalane; Joseph Makhema; Richard Marlink; Peter Gilbert; George R Seage; Victor DeGruttola; M Essex
Journal:  PLoS One       Date:  2010-04-12       Impact factor: 3.240

9.  tat Exon 1 exhibits functional diversity during HIV-1 subtype C primary infection.

Authors:  Raabya Rossenkhan; Iain J MacLeod; Theresa K Sebunya; Eduardo Castro-Nallar; Mary Fran McLane; Rosemary Musonda; Berhanu A Gashe; Vlad Novitsky; M Essex
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

10.  Timing constraints of in vivo gag mutations during primary HIV-1 subtype C infection.

Authors:  Vladimir Novitsky; Rui Wang; Lauren Margolin; Jeannie Baca; Lemme Kebaabetswe; Raabya Rossenkhan; Caitlin Bonney; Michaela Herzig; David Nkwe; Sikhulile Moyo; Rosemary Musonda; Elias Woldegabriel; Erik van Widenfelt; Joseph Makhema; Stephen Lagakos; M Essex
Journal:  PLoS One       Date:  2009-11-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.